1Department of Laboratory Medicine Malmö, Section of Medical Protein Chemistry, Skåne University Hospital, The Wallenberg Laboratory, Inga Marie Nilssons gata 53, 20502 Malmö, Sweden.
FASEB J. 2013 Dec;27(12):5083-93. doi: 10.1096/fj.13-230706. Epub 2013 Aug 20.
CUB and Sushi multiple domains 1 (CSMD1) is a transmembrane protein containing 15 consecutive complement control protein (CCP) domains, which are characteristic for complement inhibitors. We expressed a membrane-bound fragment of human CSMD1 composed of the 15 C-terminal CCP domains and demonstrated that it inhibits deposition of C3b by the classical pathway on the surface of Chinese hamster ovary cells by 70% at 6% serum and of C9 (component of membrane attack complex) by 90% at 1.25% serum. Furthermore, this fragment of CSMD1 served as a cofactor to factor I-mediated degradation of C3b. In all functional assays performed, well-characterized complement inhibitors were used as positive controls, whereas Coxsackie adenovirus receptor, a protein with no effect on complement, was a negative control. Moreover, attenuation of expression in human T47 breast cancer cells that express endogenous CSMD1 significantly increased C3b deposition on these cells by 45% at 8% serum compared with that for the controls. Furthermore, by expressing a soluble 17-21 CCP fragment of CSMD1, we found that CSMD1 inhibits complement by promoting factor I-mediated C4b/C3b degradation and inhibition of MAC assembly at the level of C7. Our results revealed a novel complement inhibitor for the classical and lectin pathways.
CUB 和 sushi 结构域 1(CSMD1)是一种跨膜蛋白,包含 15 个连续的补体控制蛋白(CCP)结构域,这是补体抑制剂的特征。我们表达了由人 CSMD1 的 15 个 C 末端 CCP 结构域组成的膜结合片段,并证明它在 6%血清中抑制经典途径在中华仓鼠卵巢细胞表面上 C3b 的沉积达 70%,在 1.25%血清中抑制 C9(膜攻击复合物的组成部分)的沉积达 90%。此外,该 CSMD1 片段可作为因子 I 介导的 C3b 降解的辅助因子。在进行的所有功能测定中,使用了经过充分表征的补体抑制剂作为阳性对照,而柯萨奇病毒腺病毒受体(一种对补体没有影响的蛋白)作为阴性对照。此外,在表达内源性 CSMD1 的人 T47 乳腺癌细胞中表达的衰减,与对照相比,在 8%血清中使这些细胞上的 C3b 沉积增加了 45%。此外,通过表达 CSMD1 的可溶性 17-21 CCP 片段,我们发现 CSMD1 通过促进因子 I 介导的 C4b/C3b 降解以及在 C7 水平抑制 MAC 组装来抑制补体。我们的结果揭示了一种用于经典和凝集素途径的新型补体抑制剂。